Strides Pharma Science Limited — Others, 21-01-2025: Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

Strides Pharma Science Limited has received an order from the Transfer Pricing Officer for the Assessment Year 2022-23, proposing an adjustment regarding transfer pricing issues. The company plans to challenge this order at the appropriate appellate forum upon receipt of the draft order by March 31, 2025. While the overall financial implications are currently indeterminate, shareholders should stay alert for developments as the situation evolves. This could create potential risk, as outcomes may impact the company’s financial standing and operations, influencing investor sentiment in the near future.